Genetic Modulators of Glaucoma
Genetic Modulators of Glaucoma
批准号:
10361394
负责人:
MONICA M JABLONSKI
金额:
$37.18万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-02-01 至 2024-01-31
关键词:
AgeAxonBlindnessCandidate Disease GeneCell DeathCellular AssayCessation of lifeChromosome 12ClinicalComputing MethodologiesDataDatabasesDiseaseFamilyFutureGenerationsGenesGeneticGenetic HeterogeneityGenomicsGlaucomaGoalsHealthHumanHuman GenomeInbred Strains RatsInbreedingInvestigationLaboratoriesLeadMethodsModelingMolecularMusOcular HypertensionOptic NerveOutcomeOutcome StudyPathway interactionsPatientsPhenotypePhysiologic Intraocular PressurePopulationPositioning AttributeProcessPublicationsQuantitative Trait LociRattusRecombinantsRegulationResearchResearch PersonnelRetinaRetinal Ganglion CellsRiskRisk FactorsRodentSystemTestingTherapeuticUnited States National Institutes of HealthValidationVisual FieldsWorkage relatedcell injurycellular targetingclinical subtypescohortdeep neural networkdensityendophenotypeexperiencegene productgenetic analysisgenome wide association studyhuman datahuman modellead candidatenerve damagenovelnovel therapeuticspreservationsuccesstargeted treatmenttherapeutic developmenttreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Glaucoma is the leading cause of irreversible blindness in the world. While elevated intraocular pressure (IOP)
is a major risk factor, damage and death of retinal ganglion cells (RGCs) underlies visual field loss. However, a
thorough understanding of this disease is a major challenge because its genetic basis is heterogeneous and it
represents a family of age-related disorders resulting from intersecting gene-regulated pathophysiologic
networks. We propose to continue to use the BXD (C57BL/6 x DBA/2J) family of recombinant inbred (RI) lines
of mice as a genetic reference panel (GRP) and to combine our work with human genome wide association
studies (GWAS), to uncover and clarify the genetic heterogeneity that underlies optic nerve (ON) damage. We
have had recent success using this combined approach in the regulation of intraocular pressure (IOP). We are
very well positioned to take the next step and apply this approach to define cellular targets of RGC damage
and death. We propose to uncover phenotypic diversities of glaucoma-related ON damage and uncover
common underlying mechanisms that are shared with IOP modulation. Our long-term research goal is to
identify disease mechanisms and develop neuroprotective therapies to preserve retinal health in patients at
risk for glaucoma. Our overall objective is to identify novel gene products and related mechanisms that lead to
glaucomatous endophenotypes using multi-dimensional genetic analyses, cross-species comparisons (mouse,
rat and human) and validation using novel murine glaucoma models. Our central hypothesis is that molecular
processes leading to glaucoma associated-endophenotypes, such as elevated IOP and ON damage, are
shared across species, and that species comparisons can uncover common underlying mechanisms, and
efficient testing of targeted glaucoma therapeutics. In the current investigation, we perform a systematic
analysis of ON damage, and an additional species—rat. We will mine the extensive databases of IOP and ON
damage that we are generating for more than 70 BXD strains across five age cohorts with the goal of defining
new models of glaucoma. An overall strength of this proposal is the combination of cutting-edge systems
genetics methods, species comparisons of glaucoma phenotypes, and a strong interdisciplinary team that
includes investigators with extensive experience in systems genetics, glaucoma, GWAS in human and rats,
and advanced computational methods. To test our hypothesis, we will perform the following thress studies: 1)
Identify the candidate gene on chromosome 12 that modulates ON damage; 2) Determine if modulation of IOP
and/or ON damage is shared across rodent species; and 3) Identify novel spontaneous glaucoma models
through a comprehensive analysis of our enlarged BXD GRP of 100 or more BXD strains. The outcomes of
these studies will define novel genes and molecular networks that underlie glaucoma-associated phenotypes
and also provide unique glaucoma models for future analysis. These results are expected to fundamentally
advance the field of glaucoma disease mechanisms and enable targeted therapeutic development.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/s41467-017-00837-5
发表时间:
2017-11-24
期刊:
Nature communications
影响因子:
16.6
作者:
[Chintalapudi SR, Maria D, Di Wang X, Bailey JNC, NEIGHBORHOOD consortium, International Glaucoma Genetics consortium, Hysi PG, Wiggs JL, Williams RW, Jablonski MM]
通讯作者:
Jablonski MM
DOI:
10.1007/s11064-010-0277-1
发表时间:
2011-04
期刊:
NEUROCHEMICAL RESEARCH
影响因子:
4.4
作者:
[Jablonski, Monica M., Freeman, Natalie E., Orr, William E., Templeton, Justin P., Lu, Lu, Williams, Robert W., Geisert, Eldon E.]
通讯作者:
Geisert, Eldon E.
DOI:
10.1016/j.biopsych.2012.05.013
发表时间:
2012-08-01
期刊:
BIOLOGICAL PSYCHIATRY
影响因子:
10.6
作者:
[Heck, Detlef H., Lu, Lu]
通讯作者:
Lu, Lu
Genetic and immunohistochemical analysis of HSPA5 in mouse and human retinas.
小鼠和人类视网膜中 HSPA5 的遗传和免疫组织化学分析。
DOI:
--
发表时间:
2016
期刊:
Molecular vision
影响因子:
2.2
作者:
[Chintalapudi,SumanaR, Wang,XiaoFei, Li,Huiling, Lau,YinHChan, Williams,RobertW, Jablonski,MonicaM]
通讯作者:
Jablonski,MonicaM
DOI:
10.3389/fnbeh.2015.00171
发表时间:
2015
期刊:
Frontiers in behavioral neuroscience
影响因子:
3
作者:
[Ashbrook DG, Williams RW, Lu L, Hager R]
通讯作者:
Hager R
共 8 条
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
-
批准号:9912475
-
项目类别:
-
资助金额:$113.77万
-
财政年份:2020
-
负责人:MONICA M JABLONSKI
-
依托单位:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
-
批准号:10374760
-
项目类别:
-
资助金额:$92.71万
-
财政年份:2020
-
负责人:MONICA M JABLONSKI
-
依托单位:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
-
批准号:10597097
-
项目类别:
-
资助金额:$93.9万
-
财政年份:2020
-
负责人:MONICA M JABLONSKI
-
依托单位:
Novel Extended Release Glaucoma Therapy for Once Daily Dosing
-
批准号:10542485
-
项目类别:
-
资助金额:$39.78万
-
财政年份:2020
-
负责人:MONICA M JABLONSKI
-
依托单位:
Genetic Modulation of Glaucoma
-
批准号:8473870
-
项目类别:
-
资助金额:$35.63万
-
财政年份:2011
-
负责人:MONICA M JABLONSKI
-
依托单位:
Genetic Modulation of Glaucoma
-
批准号:8927763
-
项目类别:
-
资助金额:$17.16万
-
财政年份:2011
-
负责人:MONICA M JABLONSKI
-
依托单位:
Genetic Modulation of Glaucoma
-
批准号:8023333
-
项目类别:
-
资助金额:$37.38万
-
财政年份:2011
-
负责人:MONICA M JABLONSKI
-
依托单位:
Genetic Modulation of Glaucoma
-
批准号:8269646
-
项目类别:
-
资助金额:$37.49万
-
财政年份:2011
-
负责人:MONICA M JABLONSKI
-
依托单位:
Genetic Modulators of Glaucoma
-
批准号:10090598
-
项目类别:
-
资助金额:$37.15万
-
财政年份:2011
-
负责人:MONICA M JABLONSKI
-
依托单位:
Proteomic Analysis of the Retina
-
批准号:7061195
-
项目类别:
-
资助金额:$14.26万
-
财政年份:2005
-
负责人:MONICA M JABLONSKI
-
依托单位:
Proteomic Analysis of the Retina
-
批准号:6918998
-
项目类别:
-
资助金额:$13.68万
-
财政年份:2005
-
负责人:MONICA M JABLONSKI
-
依托单位:
Proteomic Analysis of the Retina
-
批准号:7230462
-
项目类别:
-
资助金额:$14.18万
-
财政年份:2005
-
负责人:MONICA M JABLONSKI
-
依托单位:
CORE--CELL BIOLOGY
-
批准号:6587877
-
项目类别:
-
资助金额:$11.03万
-
财政年份:2002
-
负责人:MONICA M JABLONSKI
-
依托单位:
CORE--CELL BIOLOGY
-
批准号:6438232
-
项目类别:
-
资助金额:$11.03万
-
财政年份:2001
-
负责人:MONICA M JABLONSKI
-
依托单位:
CORE--CELL BIOLOGY
-
批准号:6327487
-
项目类别:
-
资助金额:$11.03万
-
财政年份:2000
-
负责人:MONICA M JABLONSKI
-
依托单位:
PHOTORECEPTORS--EFFECTS OF DIFFERENTIATION FACTORS
-
批准号:2165023
-
项目类别:
-
资助金额:$10.04万
-
财政年份:1995
-
负责人:MONICA M JABLONSKI
-
依托单位:
PHOTORECEPTORS--EFFECTS OF DIFFERENTIATION FACTORS
-
批准号:2634455
-
项目类别:
-
资助金额:$10.34万
-
财政年份:1995
-
负责人:MONICA M JABLONSKI
-
依托单位:
PHOTORECEPTORS--EFFECTS OF DIFFERENTIATION FACTORS
-
批准号:2165022
-
项目类别:
-
资助金额:$7.71万
-
财政年份:1995
-
负责人:MONICA M JABLONSKI
-
依托单位:
PHOTORECEPTORS--EFFECTS OF DIFFERENTIATION FACTORS
-
批准号:2856945
-
项目类别:
-
资助金额:$10.76万
-
财政年份:1995
-
负责人:MONICA M JABLONSKI
-
依托单位:
PHOTORECEPTORS--EFFECTS OF DIFFERENTIATION FACTORS
-
批准号:2019965
-
项目类别:
-
资助金额:$9.94万
-
财政年份:1995
-
负责人:MONICA M JABLONSKI
-
依托单位:
海外基金